Bovine Mastitis Market By Product (Antibiotics, Other), By Route of administration (Intramammary, Systemic), By Application (Veterinary Hospitals and Clinics, On-site Treatment): Global Opportunity Analysis and Industry Forecast, 2021-2031

Bovine Mastitis Market

Mastitis in cows is one of the most prevalent illnesses affecting the dairy food industry. Bovine mastitis is an inflammation of the mammary gland in cattle due to injury or illness that results in abnormal and reduced milk output.

The increase in the prevalence of bovine mastitis and the rise in the incidence of cow injury drive the growth of the Bovine Mastitis Market Size. For instance, according to a research article published on August 2020, in Veterinary Medicine International, a publisher of original research articles and review articles in all areas of veterinary research, the overall prevalence of mastitis reported was 80% in Kenya. Bovine mastitis is mainly caused by various bacterial & fungal infections such as Pasteurella multocida, Staphylococcus aureus, Str. zooepidemicus, Str. agalactiae, Str. Pyogenes, Str. faecalis, and Aspergillus fumigatus.

Furthermore, the rise in the number of dairy farms and surge in the production of dairy products drive the growth of the Bovine Mastitis Market Size. The increase in demand for dairy products and an upsurge in milk production propel the growth of the Bovine Mastitis Industry. For instance, according to the United States Department of Agriculture (USDA’s) Milk Production report, the annual milk production in the U.S. in 2020 was 223 billion pounds, increasing just over 2% from the 218 billion pounds produced in 2019.

Moreover, Bovine Mastitis Market Trends that drive the growth of the bovine mastitis market include R&D for the development of bovine mastitis, an increase in product approvals, and new products launched in the Bovine Mastitis Industry. In addition, the integration of artificial intelligence (AI) with veterinary health and treatment further contributes to the growth of the market. In addition, increasing initiatives by government & non-government organizations and a rise in funding for veterinary care propels the growth of the market. For instance, in October 2020, NovaQuest Capital Management LLC, a leading investor in life sciences and healthcare, announced a $20 million (USD) product financing agreement with Mileutis Ltd., an Israeli biopharmaceutical company, to help mitigate the use of antibiotics on animals. NovaQuest’s investment is expected to drive the continued development and commercialization of Mileutis’ novel, biologically sourced, and residue-free therapies for animal health. Furthermore, the rise in concern for veterinary care and improvements in animal healthcare facilities in developing nations contribute to the growth of the Bovine Mastitis Market Forecast.

The bovine mastitis market is segmented into product, route of administration, end-user, and region.

On the basis of product, the market is divided into antibiotics and others. The antibiotics segment has the largest market share in 2021, and this trend is expected to continue during the Bovine Mastitis Market Analysis period, owing to new product launches and the high efficiency of antibiotics.

By route of administration, the market is categorized into intramammary and systemic. The systemic segment have the largest market share in 2021, and this trend is expected to continue during the forecast period, owing to an increase in product approvals and advancements in bovine mastitis treatment.

Depending on the end-user, the market is classified into veterinary hospitals & clinics and on-site treatment. The on-site treatment segment has the largest market share in 2021, and this trend is expected to continue during the forecast period, owing to growth in the dairy farm industry and a rise in the number of veterinarians.

Asia-Pacific accounted for a majority of the global bovine mastitis market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the large dairy industry and the presence of key players in the region. LAMEA is anticipated to witness lucrative growth, owing to the growing dairy industry and rise in demand for dairy products.

KEY FINDINGS OF THE STUDY

On the basis of products, the antibiotics segment was the highest contributor to the market in 2021.

Based on the route of administration, the systemic segment was the highest contributor to the market in 2021.

Depending on the end user, the on-site treatment segment was the highest contributor to the market in 2021.

Region-wise, Asia-Pacific garnered the largest revenue share in 2021, whereas LAMEA is anticipated to grow at the highest CAGR during the forecast period

Overview

The global bovine mastitis market was valued at $0.54 billion in 2021 and is projected to reach $1,006.44 million by 2031, registering a CAGR of 6.3% from 2022 to 2031.

Bovine mastitis is an inflammatory response of the udder tissue in the mammary gland brought on by microbial infections or physical damage. It is regarded as the most prevalent illness that causes financial loss in the dairy sector as a result of decreased output and poor milk quality.

The increase in the number of incidences of bovine mastitis and the rise in infectious diseases in animals boost the growth of the market. For instance, according to an article published in 2020, by IntechOpen, a leading global publisher of Journals and Books within the fields of Science, Technology, and Medicine, the overall prevalence of subclinical mastitis in cows was 31.55%. The prevalence of subclinical mastitis was highest in the 5–7 years of age group (38.50%). Thus, the surge in bovine mastitis and associated infectious diseases drive the growth of the market.

Furthermore, the increase in awareness about bovine mastitis and the rise in concern for veterinary care contribute to the growth of the market. Bovine mastitis can be treated with antibiotics such as erythromycin and tylosin. It can be prevented by maintaining good hygiene, use of properly functioning milking machines; maintaining clean, dry, & comfortable housing areas; segregation & culling of persistently infected animals, and dry cow antibiotic therapy.

In addition, factors such as growth in demand for dairy products and a rise in the number of milking animals such as cows and buffalos propel the growth of the market. For instance, according to the survey of McKinsey & Company, a global management consulting firm, in 2020, compared with pre-pandemic levels, there was a 163 % increase in U.S. dairy consumers who report shopping for dairy mostly online. Thus, the rise in demand for dairy products contributes to the growth of the market.

Moreover, the increase in R&D activities for the development of advanced bovine mastitis treatment, and the rise in U.S. food and drug administration (FDA) approvals. and novel product launch in the market by key players boost the market growth. For instance, in February 2020, Ecolab Inc., the global leader in water, food safety, and health technologies and services, introduced Eco-Flex Teat Dip, an effective and affordable udder care solution for dairy cows that helps prevent infection, improve teat health, and support milk quality. Furthermore, advancements in bovine mastitis such as the integration of artificial intelligence (AI) based tools for the assessment of cow’s health further contribute to market growth. However, the antibiotic resistance in cattle and lack of awareness about bovine mastitis countries may hinder the growth of the market. Due to repeated use of antibiotics, bacteria and fungi develop the ability to defeat the drugs designed to kill them, this phenomenon is called antibiotic resistance.

The bovine mastitis market is segmented on the basis of product, route of administration, end-user, and region. By product, the market is divided into antibiotics and others. Depending on the route of administration, the market is classified into intramammary and systemic. By end user, the market is categorized into veterinary hospitals & clinics, and on-site treatment,. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Armenta Ltd., Boehringer Ingelheim GmbH, Ecolab Inc., Forte Healthcare Ltd., Huvepharma NV, Merck KGaA, Mileutis Ltd, Neogen Corporation, Thermo Fisher Scientific Inc., and Zoetis Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bovine mastitis market analysis from 2021 to 2031 to identify the prevailing bovine mastitis market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

●An in-depth analysis of the bovine mastitis market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global bovine mastitis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Zoetis Inc

Scope of Bovine Mastitis Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Antibiotics

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Other

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Intramammary

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Systemic

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Veterinary Hospitals and Clinics

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Veterinary Hospitals and Clinics Bovine Mastitis Market by Cases

6.2.4.1 Mild Cases Market size and forecast, by region

6.2.4.2 Moderate Cased Market size and forecast, by region

6.2.4.3 Severe Cases Market size and forecast, by region

6.3 On-site Treatment

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.3.4 On-site Treatment Bovine Mastitis Market by Cases

6.3.4.1 Mild Cases Market size and forecast, by region

6.3.4.2 Moderate Cases Market size and forecast, by region

6.3.4.3 Severe Cases Market size and forecast, by region

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Product

7.2.3 North America Market size and forecast, by Route of administration

7.2.4 North America Market size and forecast, by Application

7.2.4.1 North America Veterinary Hospitals and Clinics Bovine Mastitis Market by Cases

7.2.4.2 North America On-site Treatment Bovine Mastitis Market by Cases

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Product

7.2.5.1.2 Market size and forecast, by Route of administration

7.2.5.1.3 Market size and forecast, by Application

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Product

7.2.5.2.2 Market size and forecast, by Route of administration

7.2.5.2.3 Market size and forecast, by Application

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Product

7.2.5.3.2 Market size and forecast, by Route of administration

7.2.5.3.3 Market size and forecast, by Application

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Product

7.3.3 Europe Market size and forecast, by Route of administration

7.3.4 Europe Market size and forecast, by Application

7.3.4.1 Europe Veterinary Hospitals and Clinics Bovine Mastitis Market by Cases

7.3.4.2 Europe On-site Treatment Bovine Mastitis Market by Cases

7.3.5 Europe Market size and forecast, by country

7.3.5.1 France

7.3.5.1.1 Market size and forecast, by Product

7.3.5.1.2 Market size and forecast, by Route of administration

7.3.5.1.3 Market size and forecast, by Application

7.3.5.2 Germany

7.3.5.2.1 Market size and forecast, by Product

7.3.5.2.2 Market size and forecast, by Route of administration

7.3.5.2.3 Market size and forecast, by Application

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Product

7.3.5.3.2 Market size and forecast, by Route of administration

7.3.5.3.3 Market size and forecast, by Application

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Product

7.3.5.4.2 Market size and forecast, by Route of administration

7.3.5.4.3 Market size and forecast, by Application

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Product

7.3.5.5.2 Market size and forecast, by Route of administration

7.3.5.5.3 Market size and forecast, by Application

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Product

7.3.5.6.2 Market size and forecast, by Route of administration

7.3.5.6.3 Market size and forecast, by Application

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Product

7.4.3 Asia-Pacific Market size and forecast, by Route of administration

7.4.4 Asia-Pacific Market size and forecast, by Application

7.4.4.1 Asia-Pacific Veterinary Hospitals and Clinics Bovine Mastitis Market by Cases

7.4.4.2 Asia-Pacific On-site Treatment Bovine Mastitis Market by Cases

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Product

7.4.5.1.2 Market size and forecast, by Route of administration

7.4.5.1.3 Market size and forecast, by Application

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Product

7.4.5.2.2 Market size and forecast, by Route of administration

7.4.5.2.3 Market size and forecast, by Application

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by Product

7.4.5.3.2 Market size and forecast, by Route of administration

7.4.5.3.3 Market size and forecast, by Application

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by Product

7.4.5.4.2 Market size and forecast, by Route of administration

7.4.5.4.3 Market size and forecast, by Application

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Product

7.4.5.5.2 Market size and forecast, by Route of administration

7.4.5.5.3 Market size and forecast, by Application

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Product

7.4.5.6.2 Market size and forecast, by Route of administration

7.4.5.6.3 Market size and forecast, by Application

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Product

7.5.3 LAMEA Market size and forecast, by Route of administration

7.5.4 LAMEA Market size and forecast, by Application

7.5.4.1 LAMEA Veterinary Hospitals and Clinics Bovine Mastitis Market by Cases

7.5.4.2 LAMEA On-site Treatment Bovine Mastitis Market by Cases

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Product

7.5.5.1.2 Market size and forecast, by Route of administration

7.5.5.1.3 Market size and forecast, by Application

7.5.5.2 Turkey

7.5.5.2.1 Market size and forecast, by Product

7.5.5.2.2 Market size and forecast, by Route of administration

7.5.5.2.3 Market size and forecast, by Application

7.5.5.3 Rest of LAMEA

7.5.5.3.1 Market size and forecast, by Product

7.5.5.3.2 Market size and forecast, by Route of administration

7.5.5.3.3 Market size and forecast, by Application

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Armenta Ltd.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Boehringer Ingelheim Gmbh

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Ecolab Inc.

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Forte Healthcare Ltd.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Huvepharma nv

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Merck KGaA

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Mileutis Ltd

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Neogen Corporation

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Thermo Fisher Scientific Inc

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Zoetis Inc.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 2. BOVINE MASTITIS MARKET, FOR ANTIBIOTICS, BY REGION, 2021-2031 ($MILLION)

TABLE 3. BOVINE MASTITIS MARKET FOR ANTIBIOTICS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. BOVINE MASTITIS MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)

TABLE 5. BOVINE MASTITIS MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. GLOBAL BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 7. BOVINE MASTITIS MARKET, FOR INTRAMAMMARY, BY REGION, 2021-2031 ($MILLION)

TABLE 8. BOVINE MASTITIS MARKET FOR INTRAMAMMARY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 9. BOVINE MASTITIS MARKET, FOR SYSTEMIC, BY REGION, 2021-2031 ($MILLION)

TABLE 10. BOVINE MASTITIS MARKET FOR SYSTEMIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 11. GLOBAL BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 12. BOVINE MASTITIS MARKET, FOR VETERINARY HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. BOVINE MASTITIS MARKET FOR VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. GLOBAL VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 15. BOVINE MASTITIS MARKET, FOR MILD CASES, BY REGION, 2021-2031 ($MILLION)

TABLE 16. BOVINE MASTITIS MARKET, FOR MODERATE CASED, BY REGION, 2021-2031 ($MILLION)

TABLE 17. BOVINE MASTITIS MARKET, FOR SEVERE CASES, BY REGION, 2021-2031 ($MILLION)

TABLE 18. BOVINE MASTITIS MARKET, FOR ON-SITE TREATMENT, BY REGION, 2021-2031 ($MILLION)

TABLE 19. BOVINE MASTITIS MARKET FOR ON-SITE TREATMENT, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. GLOBAL ON-SITE TREATMENT BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 21. BOVINE MASTITIS MARKET, FOR MILD CASES, BY REGION, 2021-2031 ($MILLION)

TABLE 22. BOVINE MASTITIS MARKET, FOR MODERATE CASES, BY REGION, 2021-2031 ($MILLION)

TABLE 23. BOVINE MASTITIS MARKET, FOR SEVERE CASES, BY REGION, 2021-2031 ($MILLION)

TABLE 24. BOVINE MASTITIS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 27. NORTH AMERICA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 28. NORTH AMERICA VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 29. NORTH AMERICA ON-SITE TREATMENT BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 30. NORTH AMERICA BOVINE MASTITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 31. U.S. BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 32. U.S. BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 33. U.S. BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 34. CANADA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 35. CANADA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 36. CANADA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 37. MEXICO BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 38. MEXICO BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 39. MEXICO BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 40. EUROPE BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 41. EUROPE BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 42. EUROPE BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 43. EUROPE VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 44. EUROPE ON-SITE TREATMENT BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 45. EUROPE BOVINE MASTITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 46. FRANCE BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 47. FRANCE BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 48. FRANCE BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 49. GERMANY BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 50. GERMANY BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 51. GERMANY BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 52. UK BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 53. UK BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 54. UK BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 55. ITALY BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 56. ITALY BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 57. ITALY BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 58. SPAIN BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 59. SPAIN BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 60. SPAIN BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 63. REST OF EUROPE BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC ON-SITE TREATMENT BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 69. ASIA-PACIFIC BOVINE MASTITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 70. JAPAN BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 71. JAPAN BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 72. JAPAN BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 73. CHINA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 74. CHINA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 75. CHINA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 76. INDIA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 77. INDIA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 78. INDIA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 79. AUSTRALIA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 80. AUSTRALIA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 81. AUSTRALIA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 82. SOUTH KOREA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 83. SOUTH KOREA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 84. SOUTH KOREA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 85. REST OF ASIA-PACIFIC BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 86. REST OF ASIA-PACIFIC BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 87. REST OF ASIA-PACIFIC BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 88. LAMEA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 89. LAMEA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 90. LAMEA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 91. LAMEA VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 92. LAMEA ON-SITE TREATMENT BOVINE MASTITIS MARKET, BY CASES, 2021-2031 ($MILLION)

TABLE 93. LAMEA BOVINE MASTITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 94. BRAZIL BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 95. BRAZIL BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 96. BRAZIL BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 97. TURKEY BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 98. TURKEY BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 99. TURKEY BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 100. REST OF LAMEA BOVINE MASTITIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 101. REST OF LAMEA BOVINE MASTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 102. REST OF LAMEA BOVINE MASTITIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 103.ARMENTA LTD.: COMPANY SNAPSHOT

TABLE 104.ARMENTA LTD.: OPERATING SEGMENTS

TABLE 105.ARMENTA LTD.: PRODUCT PORTFOLIO

TABLE 106.ARMENTA LTD.: NET SALES,

TABLE 107.ARMENTA LTD.: KEY STRATERGIES

TABLE 108.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT

TABLE 109.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS

TABLE 110.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO

TABLE 111.BOEHRINGER INGELHEIM GMBH: NET SALES,

TABLE 112.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES

TABLE 113.ECOLAB INC.: COMPANY SNAPSHOT

TABLE 114.ECOLAB INC.: OPERATING SEGMENTS

TABLE 115.ECOLAB INC.: PRODUCT PORTFOLIO

TABLE 116.ECOLAB INC.: NET SALES,

TABLE 117.ECOLAB INC.: KEY STRATERGIES

TABLE 118.FORTE HEALTHCARE LTD.: COMPANY SNAPSHOT

TABLE 119.FORTE HEALTHCARE LTD.: OPERATING SEGMENTS

TABLE 120.FORTE HEALTHCARE LTD.: PRODUCT PORTFOLIO

TABLE 121.FORTE HEALTHCARE LTD.: NET SALES,

TABLE 122.FORTE HEALTHCARE LTD.: KEY STRATERGIES

TABLE 123.HUVEPHARMA NV: COMPANY SNAPSHOT

TABLE 124.HUVEPHARMA NV: OPERATING SEGMENTS

TABLE 125.HUVEPHARMA NV: PRODUCT PORTFOLIO

TABLE 126.HUVEPHARMA NV: NET SALES,

TABLE 127.HUVEPHARMA NV: KEY STRATERGIES

TABLE 128.MERCK KGAA: COMPANY SNAPSHOT

TABLE 129.MERCK KGAA: OPERATING SEGMENTS

TABLE 130.MERCK KGAA: PRODUCT PORTFOLIO

TABLE 131.MERCK KGAA: NET SALES,

TABLE 132.MERCK KGAA: KEY STRATERGIES

TABLE 133.MILEUTIS LTD: COMPANY SNAPSHOT

TABLE 134.MILEUTIS LTD: OPERATING SEGMENTS

TABLE 135.MILEUTIS LTD: PRODUCT PORTFOLIO

TABLE 136.MILEUTIS LTD: NET SALES,

TABLE 137.MILEUTIS LTD: KEY STRATERGIES

TABLE 138.NEOGEN CORPORATION: COMPANY SNAPSHOT

TABLE 139.NEOGEN CORPORATION: OPERATING SEGMENTS

TABLE 140.NEOGEN CORPORATION: PRODUCT PORTFOLIO

TABLE 141.NEOGEN CORPORATION: NET SALES,

TABLE 142.NEOGEN CORPORATION: KEY STRATERGIES

TABLE 143.THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT

TABLE 144.THERMO FISHER SCIENTIFIC INC: OPERATING SEGMENTS

TABLE 145.THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO

TABLE 146.THERMO FISHER SCIENTIFIC INC: NET SALES,

TABLE 147.THERMO FISHER SCIENTIFIC INC: KEY STRATERGIES

TABLE 148.ZOETIS INC.: COMPANY SNAPSHOT

TABLE 149.ZOETIS INC.: OPERATING SEGMENTS

TABLE 150.ZOETIS INC.: PRODUCT PORTFOLIO

TABLE 151.ZOETIS INC.: NET SALES,

TABLE 152.ZOETIS INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.BOVINE MASTITIS MARKET SEGMENTATION

FIGURE 2.BOVINE MASTITIS MARKET,2021-2031

FIGURE 3.BOVINE MASTITIS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.BOVINE MASTITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.BOVINE MASTITIS MARKET,BY PRODUCT,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIBIOTICS BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OTHER BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 15.BOVINE MASTITIS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INTRAMAMMARY BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SYSTEMIC BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 18.BOVINE MASTITIS MARKET,BY APPLICATION,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF VETERINARY HOSPITALS AND CLINICS BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ON-SITE TREATMENT BOVINE MASTITIS MARKET,2021-2031(%)

FIGURE 21.BOVINE MASTITIS MARKET BY REGION,2021

FIGURE 22.U.S. BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 23.CANADA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 24.MEXICO BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 25.FRANCE BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 27.UK BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 28.ITALY BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 29.SPAIN BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 30.REST OF EUROPE BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 31.JAPAN BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 32.CHINA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 33.INDIA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 35.SOUTH KOREA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 36.REST OF ASIA-PACIFIC BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 37.BRAZIL BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 38.TURKEY BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 39.REST OF LAMEA BOVINE MASTITIS MARKET,2021-2031($MILLION)

FIGURE 40. TOP WINNING STRATEGIES, BY YEAR

FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 44.COMPETITIVE DASHBOARD

FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 46.ARMENTA LTD..: NET SALES ,($MILLION)

FIGURE 47.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)

FIGURE 48.ECOLAB INC..: NET SALES ,($MILLION)

FIGURE 49.FORTE HEALTHCARE LTD..: NET SALES ,($MILLION)

FIGURE 50.HUVEPHARMA NV.: NET SALES ,($MILLION)

FIGURE 51.MERCK KGAA.: NET SALES ,($MILLION)

FIGURE 52.MILEUTIS LTD.: NET SALES ,($MILLION)

FIGURE 53.NEOGEN CORPORATION.: NET SALES ,($MILLION)

FIGURE 54.THERMO FISHER SCIENTIFIC INC.: NET SALES ,($MILLION)

FIGURE 55.ZOETIS INC..: NET SALES ,($MILLION